

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

Silvia Novello, MD, PhD¹; Dariusz M. Kowalski, MD, PhD²; Alexander Luft, MD, PhD³; Mahmut Gümüş, MD⁴; David Vicente, MD⁵; Julien Mazières, MD, PhD⁶; Jeronimo Rodríguez-Cid, MD⁷; Ali Tafreshi, MD⁸; Ying Cheng, MD⁹; Ki Hyeon Lee, MD, PhD¹⁰; Alexander Golf, MD¹¹; Shunichi Sugawara, MD, PhD¹²; Andrew G. Robinson, MD¹³; Balazs Halmos, MD¹⁴; Erin Jensen, MS¹⁵; Paul Schwarzenberger, MD¹⁶; M. Catherine Pietanza, MD¹⁶; and Luis Paz-Ares, MD, PhD¹⁷

abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.

We report 5-year efficacy and safety outcomes from the phase III KEYNOTE-407 study (ClinicalTrials.gov identifier: [NCT02775435](https://clinicaltrials.gov/ct2/show/study/NCT02775435)). Eligible patients with previously untreated, metastatic squamous non–small-cell lung cancer (NSCLC) were randomly assigned 1:1 to pembrolizumab 200 mg or placebo plus carboplatin and paclitaxel/nab-paclitaxel once every 3 weeks for four cycles, followed by pembrolizumab or placebo for up to 35 cycles. Primary end points were overall survival (OS) and progression-free survival (PFS) per RECIST version 1.1 by blinded independent central review (BICR). Five hundred fifty-nine patients were randomly assigned in the intention-to-treat population (pembrolizumab plus chemotherapy, $n = 278$; placebo plus chemotherapy, $n = 281$). The median time from random assignment to data cutoff was 56.9 (range, 49.9–66.2) months. OS and PFS were improved with pembrolizumab plus chemotherapy versus placebo plus chemotherapy (hazard ratio [95% CI], 0.71 [0.59 to 0.85] and 0.62 [0.52 to 0.74]), with 5-year OS rates of 18.4% versus 9.7%, respectively. Toxicity was manageable. Among 55 patients who completed 35 cycles of pembrolizumab, the objective response rate was 90.9% and the 3-year OS rate after completion of 35 cycles (approximately 5 years after random assignment) was 69.5%. Pembrolizumab plus chemotherapy maintained an OS and PFS benefit versus placebo plus chemotherapy in previously untreated, metastatic squamous NSCLC and is a standard-of-care first-line treatment option for metastatic squamous NSCLC regardless of programmed death ligand 1 expression.

J Clin Oncol 41:1999–2006. © 2023 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License

ASSOCIATED CONTENT

Appendix Protocol

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on December 7, 2022 and published at ascopubs.org/journal/jco on February 3, 2023; DOI <https://doi.org/10.1200/JCO.22.01990>

INTRODUCTION

The primary analysis of the global, randomized, phase III KEYNOTE-407 study demonstrated significantly improved overall survival (OS) and progression-free survival (PFS) with pembrolizumab, an anti–programmed death 1 (anti–PD-1) monoclonal antibody, in combination with carboplatin and paclitaxel or nab-paclitaxel chemotherapy versus placebo plus chemotherapy in patients with previously untreated, metastatic squamous non–small-cell lung cancer (NSCLC; OS hazard ratio [HR], 0.64 [95% CI, 0.49 to 0.85], $P < .001$; PFS HR, 0.56 [95% CI, 0.45 to 0.70], $P < .001$).¹ Pembrolizumab plus chemotherapy continued to show a clinically meaningful improvement in OS (HR, 0.71;

95% CI, 0.58 to 0.88) and PFS (HR, 0.57; 95% CI, 0.47 to 0.69) versus placebo plus chemotherapy in the protocol-specified final analysis.² We report efficacy outcomes and safety from KEYNOTE-407 with an approximately 5-year follow-up.

METHODS

Study Design and Patients

The design for this study has been previously described.^{1,2} Patients provided written informed consent.

Eligible patients had previously untreated, histologically/cytologically confirmed stage IV

CONTEXT

Key Objective

This exploratory analysis of the phase III KEYNOTE-407 study evaluated whether patients with previously untreated, metastatic squamous non–small-cell lung cancer (NSCLC) treated with pembrolizumab plus carboplatin and paclitaxel or nab-paclitaxel chemotherapy had improved long-term survival outcomes versus patients treated with placebo plus chemotherapy after a 5-year follow-up.

Knowledge Generated

With an approximately 5-year follow-up, pembrolizumab plus chemotherapy continued to provide a clinically meaningful survival benefit compared with placebo plus chemotherapy with manageable safety in patients with metastatic squamous NSCLC. Five-year overall survival rates were 18.4% with pembrolizumab plus chemotherapy versus 9.7% with placebo plus chemotherapy in the intention-to-treat population.

Relevance (T.E. Stinchcombe)

The 5-year follow-up demonstrates durable benefit for the combination of carboplatin and paclitaxel or nab-paclitaxel and pembrolizumab and the benefit in the patient subsets based on tumor programmed death ligand 1 expression. In the future, the landmark analyses of progression-free survival or overall survival at 3 or 5 years may be used to assess the long-term benefit of novel immunotherapies.*

*Relevance section written by JCO Associate Editor Thomas E. Stinchcombe, MD.

squamous NSCLC, measurable disease per RECIST version 1.1, and provided tumor tissue for determination of programmed death ligand 1 (PD-L1) status. Patients were randomly assigned 1:1 to pembrolizumab 200 mg or placebo once every 3 weeks plus carboplatin area under the curve 6 mg/mL/min plus paclitaxel 200 mg/m² or nab-paclitaxel 100 mg/m² on days 1, 8, and 15 once every 3 weeks for four cycles, followed by pembrolizumab 200 mg or placebo per initially assigned treatment until completion of 35 cycles, progressive disease (PD), unacceptable adverse event (AE), or patient withdrawal. Eligible patients in the placebo plus chemotherapy group with confirmed PD per blinded independent central review (BICR) could cross over to pembrolizumab monotherapy for up to 35 cycles. Patients were eligible to receive second-course pembrolizumab monotherapy for 17 cycles (approximately 1 year) on PD after either completing 35 cycles of pembrolizumab with a best overall response of stable disease (SD) or better or achieving a confirmed complete response (CR) per investigator assessment after receiving eight or more cycles of pembrolizumab and having received two or more cycles beyond the initial CR assessment.

End Points and Statistical Analysis

The dual primary end points were OS and PFS per RECIST version 1.1 by BICR. Secondary end points included objective response rate (ORR) and duration of response (DOR) per RECIST version 1.1 by BICR and safety. PFS2 (time from random assignment to subsequent PD after next line of treatment or death from any cause) was an exploratory end point. After documented PD or the start of new anticancer treatment, patients

were followed up for survival once every 12 weeks. Statistical methods have been previously reported.^{1,2} No alpha was assigned to this analysis.

RESULTS

Patients

There were 559 patients in the intention-to-treat (ITT) population (pembrolizumab plus chemotherapy, n = 278; placebo plus chemotherapy, n = 281). Baseline characteristics are summarized in [Table 1](#). Subsequent anticancer therapy was received by 109 patients in the pembrolizumab plus chemotherapy group (33 received anti-PD-[L]1 therapy, including 12 who received on-study second-course pembrolizumab). In the placebo plus chemotherapy group, 172 patients received subsequent therapy. Of these, 117 patients crossed over to pembrolizumab monotherapy on-study and an additional 26 had received subsequent anti-PD-(L)1 therapy outside the study for an effective crossover rate of 50.9% ([Appendix Table A1](#), online only). Fifty-five patients in the pembrolizumab plus chemotherapy group completed 35 cycles of pembrolizumab, and 12 began a second course of pembrolizumab.

Efficacy Outcomes

The median time from random assignment to database cutoff (February 23, 2022) was 56.9 (range, 49.9-66.2) months. OS was improved with pembrolizumab plus chemotherapy versus placebo plus chemotherapy (HR, 0.71; 95% CI, 0.59 to 0.85; [Fig 1](#)). Estimated 5-year OS rates were 18.4% versus 9.7%. PFS was improved with

TABLE 1. Patient Demographics and Disease Characteristics in the ITT Population

Characteristic	Pembrolizumab Plus Chemotherapy (n = 278)	Placebo Plus Chemotherapy (n = 281)	Completed 35 Cycles (2 years) of Pembrolizumab (n = 55)
Age, years, median (range)	65.0 (29-87)	65.0 (36-88)	64.0 (40-78)
< 65	127 (45.7)	127 (45.2)	29 (52.7)
Sex			
Male	220 (79.1)	235 (83.6)	43 (78.2)
Female	58 (20.9)	46 (16.4)	12 (21.8)
Region of enrollment			
East Asia	54 (19.4)	52 (18.5)	9 (16.4)
Rest of the world	224 (80.6)	229 (81.5)	46 (83.6)
ECOG performance status			
0	73 (26.3)	90 (32.0)	18 (32.7)
1	205 (73.7)	191 (68.0)	37 (67.3)
Smoking status			
Former or current	256 (92.1)	262 (93.2)	52 (94.5)
Never	22 (7.9)	19 (6.8)	3 (5.5)
Histology			
Squamous	271 (97.5)	274 (97.5)	53 (96.4)
Adenosquamous	6 (2.2)	7 (2.5)	2 (3.6)
Others	1 (0.4)	0	0
Brain metastases	20 (7.2)	23 (8.2)	2 (3.6)
PD-L1 TPS ^a			
< 1%	95 (34.2)	99 (35.2)	13 (23.6)
≥ 1%	176 (63.3)	177 (63.0)	41 (74.5)
1%-49%	103 (37.1)	104 (37.0)	25 (45.5)
≥ 50%	73 (26.3)	73 (26.0)	16 (29.1)
Could not be evaluated ^b	7 (2.5)	5 (1.8)	1 (1.8)
Taxane chemotherapy			
Paclitaxel	169 (60.8)	167 (59.4)	30 (54.5)
Nab-paclitaxel	109 (39.2)	114 (40.6)	25 (45.5)
Previous therapy			
Thoracic radiotherapy	17 (6.1)	22 (7.8)	3 (5.5)
Neoadjuvant or adjuvant therapy	5 (1.8)	8 (2.8)	1 (1.8)

NOTE. All values are No. (%) unless stated otherwise.

Abbreviations: ECOG, Eastern Cooperative Oncology Group; ITT, intention to treat; PD-L1, programmed death ligand 1; TPS, tumor proportion score.

^aBaseline tumor PD-L1 expression was assessed using PD-L1 IHC 22C3 pharmDx (Agilent Technologies, Carpinteria, CA) at a central laboratory and reported as TPS.

^bPatients unevaluable for PD-L1 status were included in the PD-L1 TPS < 1% group.

pembrolizumab plus chemotherapy versus placebo plus chemotherapy (HR, 0.62; 95% CI, 0.52 to 0.74; [Fig 1](#)). Estimated 5-year PFS rates were 10.8% versus 3.5%. HRs for OS and PFS favored pembrolizumab plus chemotherapy across all PD-L1 tumor proportion score (TPS) subgroups ([Fig 1](#); Appendix [Fig A1](#), online only).

The ORR (95% CI) was 62.2% (56.2 to 68.0) and 38.8% (33.1 to 44.8) with pembrolizumab plus chemotherapy versus placebo plus chemotherapy, respectively (Appendix

[Table A2](#), online only). The median (range) DOR was 9.0 (1.3+ to 61.5+) months and 4.9 (1.3+ to 58.6+) months, respectively ([Fig 2](#)). A higher ORR and longer DOR were observed in the pembrolizumab plus chemotherapy group in all PD-L1 TPS subgroups (Appendix [Table A2](#)).

Median PFS2 was longer for pembrolizumab plus chemotherapy versus placebo plus chemotherapy (HR, 0.60; 95% CI, 0.50 to 0.72). Five-year PFS2 rates were 18.1% (95% CI, 13.6 to 23.1) versus 7.1% (95% CI, 4.4 to 10.7).




FIG 1. Kaplan-Meier estimates of OS and PFS in the (A and E) ITT population, (B and F) patients with PD-L1 TPS $\geq$ 50%, (C and G) patients with PD-L1 TPS 1%-49%, and (D and H) patients with PD-L1 TPS $<$ 1%. chemo, chemotherapy; HR, hazard ratio; ITT, intention to treat; NR, not reached; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival; TPS, tumor proportion score. (continued on following page)

Safety

In the as-treated population (pembrolizumab plus chemotherapy, $n = 278$; placebo plus chemotherapy, $n = 280$), 98.6% and 98.2% experienced an AE (grade 3-5, 74.8% v 70.0%). No new treatment-related deaths

were reported since the protocol-specified final analysis.² Immune-mediated AEs and infusion reactions occurred in 35.6% (grade 3-5, 13.3%) and 9.3% (grade 3-5, 3.2%) of patients, respectively (Appendix Table A3, online only).




FIG 1. (Continued).

Patients Who Completed 35 Cycles of Pembrolizumab

Among patients randomly assigned to pembrolizumab plus chemotherapy, 55 (19.8%) completed 35 cycles of pembrolizumab. Baseline characteristics are provided in Table 1. The ORR was 90.9%; nine patients (16.4%) had CR, 41 (74.5%) had partial response (PR), and an additional five (9.1%) had SD. Median DOR was not reached (range, 7.1-61.5+ months). At data cutoff, 38 patients (69.1%) were alive and 24 (43.6%) were alive without PD or subsequent therapy (Fig 2). The 3-year OS rate after completion of 35 cycles of pembrolizumab (ie, approximately 5 years after random assignment) was 69.5% (95% CI, 54.8 to 80.2). All 55 patients had an AE (all treatment-related), and 35 (63.6%) had grade 3/4 AEs (no deaths). Immune-mediated AEs and infusion reactions occurred in 21 patients (38.2%; one grade 3 event).

DISCUSSION

In this 5-year analysis of KEYNOTE-407, first-line pembrolizumab plus chemotherapy provided clinically meaningful improvements in OS and PFS compared with placebo plus chemotherapy in patients with metastatic squamous NSCLC, regardless of PD-L1 TPS. Five-year OS rates were approximately doubled with pembrolizumab plus chemotherapy over placebo plus chemotherapy, although there were a limited number of patients at risk at 5 years. Toxicity was manageable and consistent with prior reports from KEYNOTE-407.^{1,2} These findings are consistent with those reported for the phase III KEYNOTE-189 study of first-line pembrolizumab plus pemetrexed-platinum versus placebo plus pemetrexed-platinum in metastatic nonsquamous NSCLC.³

Sustained improvements in OS were observed despite an effective crossover rate of 50.9% of patients in the placebo plus chemotherapy group to subsequent anti-PD-(L)1

therapy. This high crossover rate likely provides an explanation for the flattening of the Kaplan-Meier curve observed with placebo plus chemotherapy, particularly among patients with PD-L1 TPS $\geq 1\%$, which was not observed in historical chemotherapy trials before the introduction of immunotherapy.⁴ This crossover rate and plateauing of the Kaplan-Meier curve in the placebo plus chemotherapy group likely attenuated the differences in the OS HR between treatment groups observed in later analyses compared with the first reported analysis.¹ Improvement in PFS2 with pembrolizumab plus chemotherapy versus placebo plus chemotherapy indicated that the benefit of pembrolizumab plus chemotherapy was maintained after initial PD, further supporting first-line use. Notably, the HR for OS favored the pembrolizumab group across subgroups defined by baseline PD-L1 TPS, although the treatment effect was less pronounced among patients with PD-L1 TPS $\leq 1\%$ and the 95% CI contained 1.

Among patients who completed 35 cycles of pembrolizumab, responses were durable, with the majority of patients (69.0%) alive at data cutoff (ie, approximately 5 years after random assignment). These findings provide evidence of long-term benefit in the first-line setting and support the duration of treatment for pembrolizumab (35 cycles [approximately 2 years]); similar benefit was observed among patients with PD-L1–positive disease receiving pembrolizumab monotherapy.^{5,6}

In conclusion, pembrolizumab plus chemotherapy provided OS and PFS benefit versus placebo plus chemotherapy in patients with previously untreated, metastatic squamous NSCLC. As reported in the final analysis,² toxicity was manageable. These data support pembrolizumab plus chemotherapy as a standard-of-care first-line treatment option for metastatic squamous NSCLC, regardless of PD-L1 expression.




FIG 2. Patient response to pembrolizumab plus chemotherapy and placebo plus chemotherapy. (A) DOR in the ITT population and (B) time to response and DOR in patients who completed 35 cycles of pembrolizumab. Median PFS was NR (95% CI, 21.2 months to NR) among patients who completed 35 cycles. The PFS rate 3 years after completion of 35 cycles was 58.4% (95% CI, 39.8 to 73.0). chemo, chemotherapy; CR, complete response; DOR, duration of response; ITT, intention to treat; NR, not reached; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.

AFFILIATIONS

¹Department of Oncology, University of Turin, Azienda Ospedaliero Universitaria San Luigi, Turin, Italy

²Department of Lung Cancer and Thoracic Tumours, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

³Department of Oncology No. 1 (Thoracic Surgery), Leningrad Regional Clinical Hospital, Saint Petersburg, Russia

⁴Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey

⁵Department of Medical Oncology, Hospital Universitario Virgen Macarena, Sevilla, Spain

⁶Thoracic Oncology, Hôpital Larrey, Centre Hospitalier Universitaire Toulouse, Toulouse, France

⁷Oncology Center, Medica Sur Hospital, Mexico City, Mexico

⁸Wollongong Private Hospital and Wollongong Oncology, Wollongong, NSW, Australia

⁹Department of Oncology, Jilin Cancer Hospital, Changchun, China

¹⁰Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheong-ju, South Korea

¹¹Medical Oncology, Universitätsklinikum Tübingen, Tuebingen, Germany

¹²Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Miyagi, Japan

¹³Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, ON, Canada

¹⁴Montefiore Medical Center/Albert Einstein College of Medicine, The Bronx, NY

¹⁵Biostatistics and Research Decision Sciences, Merck & Co, Inc, Rahway, NJ

¹⁶Global Clinical Development, Merck & Co, Inc, Rahway, NJ

¹⁷Department of Medical Oncology, Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense & Ciberonc, Madrid, Spain

CORRESPONDING AUTHOR

Silvia Novello, MD, PhD, Department of Oncology, University of Turin, Azienda Ospedaliero Universitaria San Luigi, Regione Gonzole 10, 10043 Orbassano (TO), Turin, Italy; e-mail: silvia.novello@unito.it

PRIOR PRESENTATION

Presented at European Society for Medical Oncology, Paris, France, September 9-13, 2022.

SUPPORT

Supported by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ.

CLINICAL TRIAL INFORMATION

[NCT02775435](https://clinicaltrials.gov/ct2/show/study/NCT02775435)

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI <https://doi.org/10.1200/JCO.22.01990>.

DATA SHARING STATEMENT

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ (MSD), is committed to providing qualified scientific researchers

access to anonymized data and clinical study reports from the company's clinical trials for the purpose of conducting legitimate scientific research. MSD is also obligated to protect the rights and privacy of trial participants and, as such, has a procedure in place for evaluating and fulfilling requests for sharing company clinical trial data with qualified external scientific researchers. The MSD data sharing website (available at http://engagezone.msd.com/ds_documentation.php) outlines the process and requirements for submitting a data request. Applications will be promptly assessed for completeness and policy compliance. Feasible requests will be reviewed by a committee of MSD subject matter experts to assess the scientific validity of the request and the qualifications of the requestors. In line with data privacy legislation, submitters of approved requests must enter into a standard data-sharing agreement with MSD before data access is granted. Data will be made available for request after product approval in the United States and the European Union or after product development is discontinued. There are circumstances that may prevent MSD from sharing requested data, including country- or region-specific regulations. If the request is declined, it will be communicated to the investigator. Access to genetic or exploratory biomarker data requires a detailed, hypothesis-driven statistical analysis plan that is collaboratively developed by the requestor and MSD subject matter experts; after approval of the statistical analysis plan and execution of a data-sharing agreement, MSD will either perform the proposed analyses and share the results with the requestor or will construct biomarker covariates and add them to a file with clinical data that is uploaded to an analysis portal so that the requestor can perform the proposed analyses.

AUTHOR CONTRIBUTIONS

Conception and design: David Vicente, Paul Schwarzenberger, M. Catherine Pietanza, Luis Paz-Ares

Provision of study materials or patients: Ying Cheng, Ki Hyeong Lee, Alexander Golf, Shunichi Sugawara, Andrew G. Robinson, Balazs Halmos, Luis Paz-Ares

Collection and assembly of data: Silvia Novello, Dariusz M. Kowalski, Alexander Luft, Mahmut Gümüş, Julien Mazières, Jeronimo Rodríguez-Cid, Ali Tafreshi, Ying Cheng, Ki Hyeong Lee, Alexander Golf, Shunichi Sugawara, Andrew G. Robinson, Balazs Halmos, Paul Schwarzenberger, M. Catherine Pietanza, Luis Paz-Ares

Data analysis and interpretation: Silvia Novello, Dariusz M. Kowalski, Mahmut Gümüş, Julien Mazières, Ki Hyeong Lee, Andrew G. Robinson, Balazs Halmos, Erin Jensen, Paul Schwarzenberger, M. Catherine Pietanza, Luis Paz-Ares

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

ACKNOWLEDGMENT

We thank the patients and their families and caregivers for participating in this study, along with all investigators and site personnel. Additional study support was provided by Greg Lubiniecki, MD, and Kumar Rajagopalan, MD, of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ. Medical writing assistance was provided by Christabel Wilson, MSc, of ICON plc (Blue Bell, PA). This assistance was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ.

REFERENCES

1. Paz-Ares L, Luft A, Vicente D, et al: Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *N Engl J Med* 379:2040-2051, 2018
2. Paz-Ares L, Vicente D, Tafreshi A, et al: A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-specified final analysis of KEYNOTE-407. *J Thorac Oncol* 15:1657-1669, 2020
3. Garassino MC, Gadgeel S, Speranza G, et al: Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. *J Clin Oncol* 41:1992-1998, 2023
4. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med* 346:92-98, 2002
5. Reck M, Rodriguez-Abreu D, Robinson AG, et al: Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score $\geq$ 50. *J Clin Oncol* 39:2339-2349, 2021
6. De Castro G, Kudaba I, Wu Y-L, et al: KEYNOTE-042 5-year survival update: Pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1-positive, locally advanced or metastatic non-small-cell lung cancer. Paper presented at 36th Annual Meeting of the Society for Immunotherapy of Cancer, Washington, DC (virtual), November 10-14, 2021



ASCO® in Action

Your Source for Cancer Policy and Practice News

ASCO in Action provides the latest news and analysis on cancer policy and practice issues through a frequently updated newsfeed and biweekly newsletter. ASCO in Action provides key details for the cancer community on critical issues affecting the delivery of care, including federal funding for cancer research, the ongoing response to COVID-19, physician reimbursement, and more.

For more information, visit asco.org/ascoaction.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Silvia Novello

Consulting or Advisory Role: Sanofi

Speakers' Bureau: AstraZeneca, MSD, Bristol Myers Squibb, Roche, Pfizer, Lilly, Takeda, AbbVie, Boehringer Ingelheim, Bayer, Amgen, BeiGene, Novartis, Janssen

Dariusz M. Kowalski

Consulting or Advisory Role: Bristol Myers Squibb, Boehringer Ingelheim, Merck Serono, Roche/Genentech, AstraZeneca, MSD, Pfizer, Amgen, Johnson & Johnson/Janssen, Takeda

Mahmut Gümüş

Honoraria: MSD Oncology (Inst), Pfizer (Inst), GlaxoSmithKline (Inst), Novartis (Inst)

Consulting or Advisory Role: Roche, Lilly (Inst), Amgen (Inst), Gen (Inst), Novartis (Inst), Takeda (Inst), Gilead Sciences (Inst)

Speakers' Bureau: Roche (Inst), MSD Oncology (Inst), Novartis (Inst), Polipharma (Inst), Amgen (Inst)

Research Funding: Amgen (Inst), Pfizer (Inst)

Travel, Accommodations, Expenses: Pfizer

David Vicente

Honoraria: AstraZeneca

Consulting or Advisory Role: Bristol Myers Squibb, MSD Oncology, Roche/Genentech, Pfizer, AstraZeneca, Boehringer Ingelheim, Gilead/Forty Seven

Travel, Accommodations, Expenses: AstraZeneca

Julien Mazières

Consulting or Advisory Role: Novartis, Roche/Genentech, Pfizer, Bristol Myers Squibb, Lilly/ImClone, MSD, AstraZeneca, Pierre Fabre, Blueprint Medicines, Hengrui Therapeutics

Research Funding: Roche (Inst), Bristol Myers Squibb (Inst), AstraZeneca (Inst), Pierre Fabre (Inst)

Travel, Accommodations, Expenses: Pfizer, Roche, Bristol Myers Squibb

Jeronimo Rodríguez-Cid

Consulting or Advisory Role: Roche, Bristol Myers Squibb (Mexico), MSD Oncology, Takeda, Bayer

Speakers' Bureau: MSD Oncology, Bristol Myers Squibb (Mexico), Roche, Boehringer Ingelheim, Novartis, Bayer, Lilly, AstraZeneca

Research Funding: MSD, Bristol Myers Squibb (Mexico), Roche, Celltrion, Lilly, BeiGene, AstraZeneca

Travel, Accommodations, Expenses: Roche, MSD Oncology, AstraZeneca, Boehringer Ingelheim

Ki Hyeon Lee

Consulting or Advisory Role: Bristol Myers Squibb, MSD, AstraZeneca, Pfizer, Lilly

Research Funding: Merck

Shunichi Sugawara

Honoraria: AstraZeneca, Chugai Pharma, Nippon Boehringer Ingelheim, Taiho Pharmaceutical, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Ono Pharmaceutical, MSD K.K., Yakult Honsha, Kyowa Kirin, Towa Pharmaceutical, Takeda, Nippon Kayaku, Otsuka, Merck, Amgen, Thermo Fisher Scientific, AbbVie

Andrew G. Robinson

Honoraria: Merck

Consulting or Advisory Role: AstraZeneca, Merck, Amgen

Research Funding: AstraZeneca (Inst), Merck (Inst), Bristol Myers Squibb (Inst), Roche Canada (Inst)

Balazs Halmos

Consulting or Advisory Role: AstraZeneca, Boehringer Ingelheim, Genentech/Roche, Pfizer, Takeda, Novartis, Merck, Bristol Myers Squibb, Turning Point Therapeutics, Apollomics, Janssen Oncology, VeracYTE, BeiGene, Arcus Biosciences

Research Funding: Merck (Inst), AstraZeneca (Inst), Mirati Therapeutics (Inst), Boehringer Ingelheim (Inst), Roche/Genentech (Inst), Pfizer (Inst), Takeda (Inst), AbbVie (Inst), Bristol Myers Squibb (Inst), GlaxoSmithKline (Inst), Blueprint Medicines (Inst), Novartis (Inst), Advaxis (Inst), Janssen Oncology (Inst), Elevation Oncology (Inst), Amgen (Inst), BeiGene (Inst), Daiichi Sankyo/AstraZeneca (Inst)

Erin Jensen

Employment: Merck Sharp & Dohme LLC

Stock and Other Ownership Interests: Merck Sharp & Dohme LLC

Paul Schwarzenberger

Employment: Merck Sharp & Dohme LLC

Stock and Other Ownership Interests: Merck Sharp & Dohme LLC

Travel, Accommodations, Expenses: AstraZeneca

M. Catherine Pietanza

Employment: Merck Sharp & Dohme LLC

Stock and Other Ownership Interests: Merck Sharp & Dohme LLC

Luis Paz-Ares

Leadership: Genomica, ALTUM Sequencing

Honoraria: Roche/Genentech, Lilly, Pfizer, Bristol Myers Squibb, MSD, AstraZeneca, Merck Serono, PharmaMar, Novartis, Amgen, Sanofi, Bayer, Takeda, Mirati Therapeutics, Daiichi Sankyo, Hutchmed, BeiGene, GlaxoSmithKline, Janssen, Medscape, Regeneron

Speakers' Bureau: MSD Oncology, BMS, Roche/Genentech, Pfizer, Lilly, AstraZeneca, Merck Serono

Research Funding: BMS (Inst), AstraZeneca (Inst), PharmaMar (Inst), Kura Oncology (Inst), MSD (Inst), Pfizer (Inst)

Other Relationship: Novartis, Ipsen, Pfizer, SERVIER, Sanofi, Roche, Amgen, Merck, Roche

No other potential conflicts of interest were reported.

APPENDIX

TABLE A1. Subsequent Anticancer Therapy

Subsequent Therapy	Pembrolizumab Plus Chemotherapy (n = 278) ^a	Placebo Plus Chemotherapy (n = 280) ^a
Any subsequent pharmacologic therapy, No. (%)	109 (39.2)	172 (61.4)
Any subsequent anti-PD-(L)1 therapy	33 (11.9) ^b	143 (51.1)
First subsequent therapy, No. (%)	109 (39.2)	172 (61.4)
Pembrolizumab in study crossover ^c	0	117 (41.8)
Pembrolizumab	7 (2.5)	4 (1.4)
Other anti-PD-(L)1 antibodies with/without tyrosine kinase inhibitor	5 (1.8)	15 (5.4)
Platinum doublet with/without third agent	39 (14.0)	14 (5.0)
Platinum monotherapy	4 (1.4)	0
Nonplatinum single-agent chemotherapy	50 (18.0)	19 (6.8)
Nonplatinum chemotherapy plus VEGFR2 antagonist	4 (1.4)	2 (0.7)
Others	0	1 (0.4)
Second subsequent therapy, No. (%)	49 (17.6)	68 (24.3)
Pembrolizumab plus others	1 (0.4)	1 (0.4)
Pembrolizumab	1 (0.4)	3 (1.1)
Other anti-PD-(L)1 antibodies with/without tyrosine kinase inhibitor	7 (2.5)	6 (2.1)
Other immunotherapies	0	1 (0.4)
Other anti-PD-(L)1 antibodies with/without single-agent chemotherapy	1 (0.4)	0
Platinum doublet with/without third agent	8 (2.9)	19 (6.8)
Platinum monotherapy	0	2 (0.7)
Nonplatinum single-agent chemotherapy	27 (15.1)	31 (11.1)
Nonplatinum chemotherapy plus VEGFR2 antagonist	3 (1.1)	4 (1.4)
Tyrosine kinase inhibitor	1 (0.4)	0
Others	0	1 (0.4)
Third subsequent therapy, No. (%)	16 (5.8)	21 (7.5)
Pembrolizumab plus chemotherapy	0	1 (0.4)
Other anti-PD-(L)1 antibodies	4 (1.4)	2 (0.7)
Platinum doublet with/without third agent	2 (0.7)	4 (1.4)
Platinum monotherapy	1 (0.4)	0
Nonplatinum single-agent chemotherapy	6 (2.2)	13 (4.7)
Nonplatinum agent plus VEGF inhibitor	1 (0.4)	0
Tyrosine kinase inhibitor	2 (0.7)	1 (0.4)
Fourth subsequent therapy, No. (%)	8 (2.9)	7 (2.5)
Pembrolizumab	0	0
Other anti-PD-(L)1 antibodies	1 (0.4)	2 (0.7)
Platinum doublet with/without third agent	2 (0.7)	2 (0.7)
Nonplatinum single-agent chemotherapy	3 (1.1)	2 (0.7)
Nonplatinum chemotherapy plus VEGFR2 antagonist	0	1 (0.4)
Tyrosine kinase inhibitor	1 (0.4)	0
Others	1 (0.4)	0
Fifth subsequent therapy, No. (%)	5 (1.8)	2 (0.7)
Other anti-PD-(L)1 antibodies	0	0

(continued on following page)

TABLE A1. Subsequent Anticancer Therapy (continued)

Subsequent Therapy	Pembrolizumab Plus Chemotherapy (n = 278) ^a	Placebo Plus Chemotherapy (n = 280) ^a
Nonplatinum single-agent chemotherapy	3 (1.1)	2 (0.7)
Nonplatinum chemotherapy plus VEGFR2 antagonist	1 (0.4)	0
Tyrosine kinase inhibitor	1 (0.4)	0
Sixth subsequent therapy, No. (%)	1 (0.4)	2 (0.7)
Other anti-PD-(L)1 antibodies	0	1 (0.4)
Nonplatinum single-agent chemotherapy	1 (0.4)	1 (0.4)

Abbreviations: BICR, blinded independent central review; PD, progressive disease; PD-L1, programmed death ligand 1; VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor 2.

^aPercentages were calculated on the basis of the as-treated population.

^bIncluding patients who received on-study second-course pembrolizumab.

^cEligible patients in the placebo plus chemotherapy group with confirmed PD per BICR were allowed to cross over to pembrolizumab monotherapy for up to 35 cycles.

TABLE A2. Tumor Response and DOR in the ITT Population and According to PD-L1 Status

Outcome	ITT Population (n = 559)		PD-L1 TPS ≥ 50% (n = 146)		PD-L1 TPS 1%-49% (n = 207)		PD-L1 TPS < 1% (n = 194)	
	Pembrolizumab Plus Chemotherapy (n = 278)	Placebo Plus Chemotherapy (n = 281)	Pembrolizumab Plus Chemotherapy (n = 73)	Placebo Plus Chemotherapy (n = 73)	Pembrolizumab Plus Chemotherapy (n = 103)	Placebo Plus Chemotherapy (n = 104)	Pembrolizumab Plus Chemotherapy (n = 95)	Placebo Plus Chemotherapy (n = 99)
ORR (95% CI), ^a %	62.2 (56.2 to 68.0)	38.8 (33.1 to 44.8)	64.4 (52.3 to 75.3)	30.1 (19.9 to 42.0)	54.4 (44.3 to 64.2)	43.3 (33.6 to 53.3)	67.4 (57.0 to 76.6)	41.4 (31.6 to 51.8)
Best overall response, No. (%)								
CR	10 (3.6)	11 (3.9)	3 (4.1)	3 (4.1)	6 (5.8)	3 (2.9)	1 (1.1)	5 (5.1)
PR	163 (58.6)	98 (34.9)	44 (60.3)	19 (26.0)	50 (48.5)	42 (40.4)	63 (66.3)	36 (36.4)
SD ^b	66 (23.7)	102 (36.3)	14 (19.2)	26 (35.6)	30 (29.1)	40 (38.5)	21 (22.1)	34 (34.3)
PD	17 (6.1)	40 (14.2)	3 (4.1)	12 (16.4)	9 (8.7)	9 (8.7)	5 (5.3)	18 (18.2)
Not evaluable ^c	6 (2.2)	7 (2.5)	2 (2.7)	3 (4.1)	1 (1.0)	2 (1.9)	3 (3.2)	2 (2.0)
No assessment ^d	16 (5.8)	23 (8.2)	7 (9.6)	10 (13.7)	7 (6.8)	8 (7.7)	2 (2.1)	4 (4.0)
DOR, months, median (range) ^e	9.0 (1.3+ to 61.5+)	4.9 (1.3+ to 58.6+)	10.4 (2.7 to 59.4+)	4.6 (1.3+ to 58.6+)	11.1 (1.3+ to 61.5+)	4.8 (2.0 to 58.6+)	6.9 (1.4+ to 58.9+)	5.7 (1.4+ to 55.8+)
Response duration ≥ 4 years, No. (%)	24 (21.6)	7 (16.0)	8 (24.0)	3 (17.5)	8 (23.9)	2 (8.1)	6 (16.8)	2 (21.0)
Time to response, months, median (range)	1.4 (1.1-10.9)	1.4 (1.0-18.7)	1.5 (1.1-8.4)	1.4 (1.2-3.0)	1.4 (1.1-10.9)	1.4 (1.0-18.7)	1.4 (1.2-10.6)	1.4 (1.2-10.4)

NOTE. + indicates that there was no PD at the time of last assessment. Tumor imaging was performed at baseline; at weeks 6, 12, and 18 from the time of random assignment; then every 9 weeks for the first 45 weeks in the treatment period; and every 12 weeks thereafter in the first course.

Abbreviations: BICR, blinded independent central review; CR, complete response; DOR, duration of response; ITT, intention to treat; NR, not reached; ORR, objective response rate; PD, progressive disease; PD-L1, programmed death ligand 1; PR, partial response; SD, stable disease; TPS, tumor proportion score.

^aPer RECIST version 1.1 by BICR.

^bIncludes both SD and non-CR/non-PD.

^cPostbaseline assessment(s) available but not evaluable (ie, all postbaseline assessments not evaluable or CR/PR/SD < 6 weeks from random assignment).

^dNo postbaseline assessment available for response assessment.

^eKaplan-Meier estimate.

TABLE A3. AEs in the As-Treated Population

AE	Pembrolizumab Plus Chemotherapy (n = 278)	Placebo Plus Chemotherapy (n = 280)
Any	274 (98.6)	275 (98.2)
Grade 3-5	208 (74.8)	196 (70.0)
Led to treatment discontinuation		
Any treatment	80 (28.8)	37 (13.2)
All treatments ^a	48 (17.3)	21 (7.5)
Led to death	32 (11.5)	20 (7.1)
Any treatment-related AE	266 (95.7)	252 (90.0)
Grade 3-5	159 (57.2)	156 (55.7)
Led to treatment discontinuation	58 (20.9)	21 (7.5)
Led to death	12 (4.3) ^b	5 (1.8) ^c

AEs Occurring in ≥ 15% of Patients	Any Grade	Grade 3-5	Any Grade	Grade 3-5
Anemia	152 (54.7)	44 (15.8)	145 (51.8)	58 (20.7)
Alopecia	128 (46.0)	1 (0.4)	105 (37.5)	3 (1.1)
Neutropenia	105 (37.8)	64 (23.0)	91 (32.5)	69 (24.6)
Nausea	101 (36.3)	4 (1.4)	91 (32.5)	3 (1.1)
Diarrhea	93 (33.5)	12 (4.3)	71 (25.4)	7 (2.5)
Thrombocytopenia	86 (30.9)	23 (8.3)	65 (23.2)	19 (6.8)
Decreased appetite	77 (27.7)	7 (2.5)	82 (29.3)	4 (1.4)
Arthralgia	71 (25.5)	5 (1.8)	48 (17.1)	2 (0.7)
Constipation	70 (25.2)	2 (0.7)	62 (22.1)	3 (1.1)
Fatigue	68 (24.5)	13 (4.7)	74 (26.4)	12 (4.3)
Asthenia	63 (22.7)	6 (2.2)	63 (22.5)	12 (4.3)
Peripheral neuropathy	61 (21.9)	3 (1.1)	48 (17.1)	2 (0.7)
Rash	52 (18.7)	2 (0.7)	32 (11.4)	0
Pruritus	51 (18.3)	1 (0.4)	25 (8.9)	1 (0.4)
Vomiting	51 (18.3)	1 (0.4)	33 (11.8)	6 (2.1)
Cough	49 (17.6)	2 (0.7)	56 (20.0)	3 (1.1)
Pyrexia	42 (15.1)	2 (0.7)	38 (13.6)	5 (1.8)
Dyspnea	41 (14.7)	4 (1.4)	47 (16.8)	4 (1.4)

Immune-Mediated AEs and Infusion Reactions	Any Grade	Grade 3-5	Any Grade	Grade 3-5
Any	99 (35.6)	37 (13.3)	26 (9.3)	9 (3.2)
Hypothyroidism	34 (12.2)	1 (0.4)	6 (2.1)	0
Pneumonitis	23 (8.3)	9 (3.3)	6 (2.1)	3 (1.1)
Hyperthyroidism	21 (7.6)	1 (0.4)	2 (0.7)	0
Infusion reactions	15 (5.4)	5 (1.8)	7 (2.5)	1 (0.4)
Colitis	9 (3.2)	7 (2.5)	4 (1.4)	3 (1.1)
Hepatitis	6 (2.2)	6 (2.2)	0	0
Severe skin reactions	6 (2.2)	4 (1.4)	1 (0.4)	1 (0.4)
Hypophysitis	4 (1.4)	2 (0.8)	0	0
Thyroiditis	3 (1.1)	1 (0.4)	0	0

(continued on following page)

TABLE A3. AEs in the As-Treated Population (continued)

Immune-Mediated AEs and Infusion Reactions	Any Grade	Grade 3-5	Any Grade	Grade 3-5
Nephritis	2 (0.7)	2 (0.7)	2 (0.7)	2 (0.7)
Vasculitis	2 (0.7)	1 (0.4)	0	0
Adrenal insufficiency	1 (0.4)	0	0	0

NOTE. All values are No. (%). AEs were monitored from random assignment through 30 days (90 days for serious AEs) after treatment cessation and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.

Abbreviation: AE, adverse event.

^aIncludes patients who discontinued pembrolizumab or placebo, carboplatin, and taxane owing to an AE at any time and patients who discontinued pembrolizumab or placebo owing to an AE after completing four 3-week cycles of carboplatin and taxane.

^bIncluding sepsis, n = 3; death (cause not specified), n = 2; cardiac arrest, cardiac failure, hepatic failure, necrotizing fasciitis, pneumonitis, pulmonary hemorrhage, and respiratory failure, n = 1 each.

^cIncluding septic shock, n = 2; pneumonia, acute renal injury, and pulmonary hemorrhage, n = 1 each.




FIG A1. Kaplan-Meier estimates of (A) OS and (B) PFS in patients with PD-L1 TPS $\geq$ 1%. chemo, chemotherapy; HR, hazard ratio; NR, not reached; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival; TPS, tumor proportion score.